EA201490531A1 - Регуляция экспрессии рецептора посредством доставки искусственных факторов транскрипции - Google Patents

Регуляция экспрессии рецептора посредством доставки искусственных факторов транскрипции

Info

Publication number
EA201490531A1
EA201490531A1 EA201490531A EA201490531A EA201490531A1 EA 201490531 A1 EA201490531 A1 EA 201490531A1 EA 201490531 A EA201490531 A EA 201490531A EA 201490531 A EA201490531 A EA 201490531A EA 201490531 A1 EA201490531 A1 EA 201490531A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptor
diseases
endothelin
transcription factors
artificial transcription
Prior art date
Application number
EA201490531A
Other languages
English (en)
Inventor
Йозеф Фламмер
Альберт Нойтцнер
Элис Хюкслей
Original Assignee
Алиофта Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Алиофта Аг filed Critical Алиофта Аг
Publication of EA201490531A1 publication Critical patent/EA201490531A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к искусственным факторам транскрипции, включающим белок, который содержит несколько цинкосодержащих пальцеобразных доменов, специфически нацеленный на промотор гена рецептора, слитый с ингибиторным или активаторным доменом, сигналом ядерной локализации и доменом белковой трансдукции. В конкретных примерах указанные промоторы гена рецептора регулируют экспрессию рецептора эндотелина А, рецептора эндотелина В, Toll-подобного рецептора 4 или высокоаффинного рецептора IgE. Искусственные факторы транскрипции, направленные на рецепторы эндотелина А или В, можно применять при лечении заболеваний, модулируемых эндотелином, таких как сердечно-сосудистые заболевания, и, в частности, заболеваний глаз, например окклюзии вен сетчатки, окклюзии артерий сетчатки, отека макулы, оптической нейропатии, центральной серозной хориоретинопатии, пигментного ретинита, наследственной оптической нейропатии Лебера и похожих заболеваний. Искусственные факторы транскрипции, направленные на Toll-подобный рецептор 4 или IgE-рецептор, можно применять при лечении аутоиммунных и похожих заболеваний, и аллергических заболеваний, соответственно.
EA201490531A 2011-10-11 2012-10-10 Регуляция экспрессии рецептора посредством доставки искусственных факторов транскрипции EA201490531A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11184706 2011-10-11
PCT/EP2012/069981 WO2013053719A2 (en) 2011-10-11 2012-10-10 Regulation of receptor expression through delivery of artificial transcription factors

Publications (1)

Publication Number Publication Date
EA201490531A1 true EA201490531A1 (ru) 2014-08-29

Family

ID=47045011

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490531A EA201490531A1 (ru) 2011-10-11 2012-10-10 Регуляция экспрессии рецептора посредством доставки искусственных факторов транскрипции

Country Status (20)

Country Link
US (1) US20140296129A1 (ru)
EP (1) EP2766484A2 (ru)
JP (1) JP2014530607A (ru)
KR (1) KR20140079780A (ru)
CN (1) CN103998609A (ru)
AU (1) AU2012323032A1 (ru)
BR (1) BR112014008456A2 (ru)
CA (1) CA2851560A1 (ru)
CL (1) CL2014000897A1 (ru)
CO (1) CO6930308A2 (ru)
EA (1) EA201490531A1 (ru)
HK (1) HK1197083A1 (ru)
IL (1) IL231865A0 (ru)
IN (1) IN2014CN02586A (ru)
MA (1) MA36970A1 (ru)
MX (1) MX2014004331A (ru)
SG (1) SG11201400701WA (ru)
TN (1) TN2014000117A1 (ru)
WO (1) WO2013053719A2 (ru)
ZA (1) ZA201401960B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015311706A1 (en) 2014-09-07 2017-02-02 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
EP3694543A1 (en) 2017-10-13 2020-08-19 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20210364497A1 (en) * 2018-04-02 2021-11-25 University Of Miami IFN-beta Reporter System for Primary Cells
EP3976802A1 (en) 2019-05-28 2022-04-06 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
US20220049310A1 (en) * 2020-02-25 2022-02-17 Sichuan Provincial People's Hospital Use of ZNF124 Gene in Early Screening or Auxiliary Diagnosis of Retinitis Pigmentosa Disease
CN111304314B (zh) * 2020-02-25 2020-11-20 四川省人民医院 Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE407205T1 (de) * 1994-08-20 2008-09-15 Gendaq Ltd Verbesserung in bezug auf bindungsproteine bei der erkennung von dna
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
CA2396898A1 (en) * 2000-01-21 2001-07-26 The Scripps Research Institute Methods and compositions to modulate expression in plants
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
WO2002066640A2 (en) * 2001-02-21 2002-08-29 Novartis Ag Zinc finger binding domains for nucleotide sequence ann
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
US7592003B2 (en) * 2005-09-30 2009-09-22 Oklahoma Medical Research Foundation Regulation of toll-like receptors on stem cells
WO2008140538A1 (en) * 2006-10-04 2008-11-20 Verenium Corporation Dna display screen for expression product with desired binding properties
GB0620705D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
CN101333251A (zh) * 2008-01-30 2008-12-31 中国人民解放军第三军医大学 能启动a20基因表达的人工锌指蛋白转录因子及用途
WO2010056808A2 (en) * 2008-11-12 2010-05-20 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
WO2010111503A2 (en) * 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE HIGH AFFINITY IGE RECEPTOR ALPHA CHAIN (FCεRLα) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2011070049A1 (en) * 2009-12-09 2011-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis

Also Published As

Publication number Publication date
US20140296129A1 (en) 2014-10-02
CA2851560A1 (en) 2013-04-18
IN2014CN02586A (ru) 2015-08-07
CN103998609A (zh) 2014-08-20
HK1197083A1 (en) 2015-01-02
SG11201400701WA (en) 2014-08-28
TN2014000117A1 (en) 2015-07-01
ZA201401960B (en) 2015-06-24
JP2014530607A (ja) 2014-11-20
MX2014004331A (es) 2014-11-26
WO2013053719A2 (en) 2013-04-18
EP2766484A2 (en) 2014-08-20
WO2013053719A3 (en) 2013-06-27
CO6930308A2 (es) 2014-04-28
KR20140079780A (ko) 2014-06-27
BR112014008456A2 (pt) 2017-04-11
CL2014000897A1 (es) 2014-11-21
MA36970A1 (fr) 2016-03-31
IL231865A0 (en) 2014-05-28
AU2012323032A1 (en) 2014-04-03

Similar Documents

Publication Publication Date Title
EA201490531A1 (ru) Регуляция экспрессии рецептора посредством доставки искусственных факторов транскрипции
CY1124610T1 (el) Αντισωματα συγκεκριμενα για tgf-bhta
DOP2016000280A (es) Vectores de aav para la terapia génica de la retina y el snc
BR112017027945A2 (pt) formulação líquida estável de proteína de fusão com domínio igg fc e composição para estabilizar uma proteína
MY179138A (en) Lenses, devices, methods and systems for refractive error
MX2011013781A (es) Anticuerpos anti-vegf y sus usos.
CR20140047A (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
BR112014008759A2 (pt) tratamento de doença ocular
PH12015502421A1 (en) Artificial transcription factors engineered to overcome endosomal entrapment
CY1121787T1 (el) Sirna και χρηση αυτων σε μεθοδους και συνθεσεις για τη θεραπεια ή/και προληψη οφθαλμικων καταστασεων
EP2401648A4 (en) LENS PORT OF ORTHOKERATOLOGY COMBINED WITH CHEMICAL TREATMENT TO CORRECT MYOPIA, HYPERMETROPY OR ASTIGMATIA
EP4389894A3 (en) Riboswitch modulated gene therapy for retinal diseases
MX2021001292A (es) Metodos para la modificacion genica de celulas hematopoyeticas.
EA201591626A1 (ru) Искусственные факторы транскрипции для лечения заболеваний, вызываемых гаплонедостаточностью opa1
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
WO2012099940A3 (en) Methods and compositions for treating ocular disease
MX2022005968A (es) Promotores especificos para neuronas bipolares activadas para el suministro ocular de genes.
AR095985A1 (es) Factores artificiales de transcripción y su uso para tratar la curación inadecuada de heridas oculares
MX2022004770A (es) Vectores de virus adeno-asociados (aav) para el tratamiento de la degeneracion macular relacionada con la edad y otras enfermedades y trastornos oculares.
WO2020032892A3 (en) Disposable catheter fixing cap
Foudah et al. Research Article Expression of Neural Markers by Undifferentiated Mesenchymal-Like Stem Cells from Different Sources
Schiera et al. G26/24 extracellular microvesicles contain both H1° protein and RNA
Cerani Neuron-Derived Semaphorin 3A is an Early Inducer of Vascular Permeability in Diabetic Retinopathy
MY178716A (en) Composition for treatment of ocular diseases and preparation thereof
Nan-Kai et al. Transplantation of reprogrammed embryonic stem cells improves visual function in a mouse model for Retinitis Pigmentosa: Transplantation 2010 April 27; 89 (8): 911-919.